Kiromic BioPharma shares are trading higher after the company announced it will submit an amended Investigational New Drug Application for its first oncology cell therapy candidate Procel directly to the FDA in the second half of 2022.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!

  • The most trusted brand in stock market news
  • Fatest intelligence & alerts
  • Active trader chat rooms
  • Option trade alerts
  • Only comprehensive mobile notifications solution
  • Welcoming & white glove support
Posted In: WIIM
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...